Lapatinib Plus Capecitabine for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

Basit Öğe Kaydı
dc.contributor.authorÇetin, Bülent
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorKoral, Lokman
dc.contributor.authorUlaş, Arife
dc.contributor.authorDane, Faysal
dc.contributor.authorTürker, İbrahim
dc.contributor.authorKaplan, Mehmet A.
dc.contributor.authorKoca, Doğan
dc.contributor.authorBoruban, Cem
dc.contributor.authorYılmaz, Burçak
dc.contributor.authorSevinç, Alper
dc.contributor.authorBerk, Veli
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorUncu, Doğan
dc.contributor.authorHarputluoğlu, Hakan
dc.contributor.authorCoşkun, Uğur
dc.contributor.authorBüyükberber, Süleyman
dc.date.accessioned2020-03-26T18:30:48Z
dc.date.available2020-03-26T18:30:48Z
dc.date.issued2012
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: We investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) treated with lapatinib and capecitabine (LC). Patients and Methods: A total of 203 patients with HER2+ MBC, who had progressed after trastuzumab-containing chemotherapy, were retrospectively evaluated in 11 centers between September 2009 and May 2011. 85 patients who had developed BMs before the initiation of treatment with LC were included. All patients had received prior cranial radiotherapy. All patients were treated with the combination of lapatinib (1,250 mg/day continuously) and capecitabine (2,000 mg/m(2) on days 1-14 of a 21-day cycle). Results: The median follow-up was 10.5 months (range 1-38 months). An overall response rate of 27.1% was achieved, including complete response in 2 (2.4%) and partial response in 21 (24.7%) patients. Median progression-free survival was 7 months (95% confidence interval (CI) 5-9), with a median overall survival of 13 months (95% Cl 9-17). The most common side effects were hand-foot syndrome (58.8%), nausea (55.3%), fatigue (48.9%), anorexia (45.9%), rash (36.5%), and diarrhea (35.4%). Grade 3-4 toxicities were hand-foot syndrome (9.4%), diarrhea (8.3%), fatigue (5.9%), and rash (4.7%). There were no symptomatic cardiac events. Conclusion: LC combination therapy was effective and well-tolerated in patients with HER2+ MBC with BMs, who had progressive disease after trastuzumab-containing therapy.en_US
dc.description.abstractHintergrund: Wir haben das klinische Outcome von Patientinnen mit Hirnmetastasen eines HER2 (human epidermal growth factor receptor 2)-positiven metastasierten Mammakarzinoms unter Behandlung mit Lapatinib und Capecitabin (LC) evaluiert. Patientinnen und Methoden: Insgesamt wurden 203 Patientinnen mit HER2-positivem metastasierten Mammakarzinom, bei denen es zu einem Krankheitsfortschreiten unter Trastuzumab enthaltender Therapie gekommen war, zwischen September 2009 und Mai 2011 in 11 Behandlungszentren retrospektiv evaluiert. 85 Patientinnen, die vor dem Beginn der LC-Behandlung Hirnmetastasen entwickelt hatten, wurden in die Studie aufgenommen. Alle Patientinnen waren zuvor einer kranialen Radiotherapie unterzogen worden, und alle erhielten gleichermaßen eine Kombination aus Lapatinib (1250 mg/d kontinuierlich) und Capecitabine (2000 mg/m2 an Tag 1–14 eines 21 tägigen Zyklus). Ergebnisse: Das mittlere Follow-Up betrug 10,5 Monate (Spanne 1–38 Monate). Eine Gesamtansprechrate von 27,1% wurde erreicht, inklusive eines kompletten Ansprechens bei 2 (2,4%) und eines Teilansprechens bei 21 (24,7%) Patientinnen. Das mittlere progressionsfreie Überleben war 7 Monate (95%- Konfidenzinterval (KI) 5–9) mit einem mittleren Gesamtüberleben von 13 Monaten (95%-Kl 9–17). Die häufigsten Nebenwirkungen waren Hand-Fuß-Syndrom (58,8%), Übelkeit (55,3%), Fatigue (48,9%), Anorexie (45,9%), Hautausschlag (36,5%) und Durchfall (35,4%). Als Toxizitäten vom Grad 3–4 traten HandFuß-Syndrom (9.4%), Durchfall (8,3%), Fatigue (5,9%) und Hautausschlag (4,7%) auf. Symptomatische kardiovaskuläre Nebenwirkungen wurden nicht beobachtet. Schlussfolgerung: Die LCKombinationstherapie war bei Patientinnen mit HER2-positivem metastasierten Mammakarzinom mit Hirnmetastasen, bei denen es nach trastuzumabhaltiger Therapie zu einem Progress gekommen war, effektiv und wurde gut toleriert.
dc.identifier.citationÇetin, B., Benekli, M., Öksüzoğlu, B., Koral, L., Ulaş, A., Dane, F., Türker, I., Kaplan, M. A., Koca, D., Boruban, C., Yılmaz, B., Sevinç, A., Berk, V., Işıkdoğan, A., Uncu, D., Harputluoğlu, H., Coşkun, U., Büyükberber, S., (2012). Lapatinib Plus Capecitabine for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience. Karger, (35), 740-745. Doi: 10.1159/000345040
dc.identifier.doi10.1159/000345040en_US
dc.identifier.endpage745en_US
dc.identifier.issn0378-584Xen_US
dc.identifier.issn1423-0240en_US
dc.identifier.pmid23207619en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage740en_US
dc.identifier.urihttps://dx.doi.org/10.1159/000345040
dc.identifier.urihttps://hdl.handle.net/20.500.12395/28190
dc.identifier.volume35en_US
dc.identifier.wosWOS:000312469400003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKoral, Lokman
dc.institutionauthorBoruban, Cem
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofOnkologıeen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectHer2en_US
dc.subjectMetastatic breast canceren_US
dc.subjectLapatiniben_US
dc.subjectBrain metastasesen_US
dc.subjectMetastasiertes Mammakarzinom
dc.subjectHirnmetastasen
dc.titleLapatinib Plus Capecitabine for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
28190.pdf
Boyut:
340.25 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Radyasyon Onkolojisi/Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu